|
|
 |
| |
Actelion and Merck form strategic alliance |
THE ACTELION ANNUAL REPORT 2003 |
|
|
|
| |
|
|
|
|
|
|
| Actelion and Merck form strategic alliance… |
| |
In December 2003, Actelion and pharmaceutical giant Merck announced an exclusive worldwide alliance to discover, develop and market new classes of renin inhibitors. Actelion’s scientists have pioneered orally available molecules that block renin, a critical enzyme indicated in a number of widespread cardiovascular and kidney diseases.
This alliance illustrates the essence of Actelion’s successful positioning as a leading biopharmaceutical company: relying on a highly professional research and development staff complemented with an equally qualified marketing group for specialized medical indications and, when appropriate, seeking industry partners for broader markets.
|
|
|
|
